The VIRTUE Post Marketing Surveillance Registry

NCT ID: NCT01213589

Last Updated: 2013-12-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-12-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-market release registry is to collect additional information concerning safety, performance and health economic data with respect to the Medtronic VALIANT Thoracic Stent Graft with the Xcelerant Delivery System in the treatment of descending thoracic aortic dissections.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The patient device for use in this registry is the Medtronic VALIANT Thoracic Stent Graft System that received CE mark approval in March 2005.

The Medtronic VALIANT Thoracic Stent Graft with Xcelerant Delivery System is designed to treat diseases of the descending thoracic aorta including but not limited to aneurysms and dissections. The VALIANT Stent Graft is designed to exclude the aneurysm, the false lumen or site of rupture and restore the blood flow through the stent graft lumen. The device is intended for use either in patients who are candidates for conventional surgical repair, and in patients who are not candidates for conventional surgical repair due to pre-existing risk factors.

This registry is a prospective, non-randomized, single-arm, multi-center, European clinical registry with patients diagnosed with descending thoracic aortic dissection.

For this registry standard hospital procedures with respect to patient interventional care for thoracic aortic diseases will be followed.

This is a descriptive registry in which no specific hypotheses will be statistically tested.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Dissection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

descending thoracic aortic dissection Valiant Medtronic Type B VIRTUE stent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Descending thoracic aortic dissection

Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient will be more than or equal to 18 years of age; or older if required by local regulations.
* Patient has an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
* Patient is amenable for stent-graft treatment (in accordance with the IFU).
* The patient is willing and able to cooperate with registry procedures and required follow-up visits.
* The patient or legal guardian has signed a patient informed consent form, including data privacy authorization (this criteria is not applicable for patients presenting in emergency with ruptured dissection and for whom legal representative is not available informed consent can be requested after surgical procedure).

Exclusion Criteria

* Patients with a thoracic dissection for which optimal treatment is observation and medical management.
* Patient with current - non aortic - medical condition with a life expectancy less than one year.
* The patient is participating in another device or drug study (patient must have completed the follow-up phase of any previous study at least 30 days prior to enrolment in this registry).
* Time interval between medical indication for surgical intervention and endovascular procedure exceeds 4 months (122 days).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Endovascular

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

M. Thompson, Prof.

Role: PRINCIPAL_INVESTIGATOR

St George's Hospital

D. Gasparini, Dr.

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedaliera "Santa Maria della Misericordia"

R. Fattori, Prof.

Role: PRINCIPAL_INVESTIGATOR

Ospedale Sant'Orsola Malpighi

P. Cao, Dr.

Role: PRINCIPAL_INVESTIGATOR

Unità di Chirurgia Vascolare, Ospedale R. Silvestrini

G. Garzón, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario La Paz

E. Ros, Prof.

Role: PRINCIPAL_INVESTIGATOR

Hospital Clínico Universitario San Cecilio

B. Rylski, Dr.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Freiburg

S. Huptas, Dr.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Essen

I. Degrieck, Dr.

Role: PRINCIPAL_INVESTIGATOR

Onze-Lieve-Vrouw Ziekenhuis

D. Dai-DoDo, Prof.

Role: PRINCIPAL_INVESTIGATOR

Universitätsspital Bern, Inselspital

H. Roos, Dr.

Role: PRINCIPAL_INVESTIGATOR

Sahlgrenska University Hospital

R. Heijmen, Dr.

Role: PRINCIPAL_INVESTIGATOR

St. Antonius Hospital

N. Cheshire, Prof.

Role: PRINCIPAL_INVESTIGATOR

St Mary's NHS Trust

C. Nienaber, Dr

Role: PRINCIPAL_INVESTIGATOR

University School of Medicine Rostock

References

Explore related publications, articles, or registry entries linked to this study.

Virtue Registry Investigators. The VIRTUE Registry of type B thoracic dissections--study design and early results. Eur J Vasc Endovasc Surg. 2011 Feb;41(2):159-66. doi: 10.1016/j.ejvs.2010.08.016. Epub 2010 Oct 16.

Reference Type RESULT
PMID: 20952217 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MDTVIRTUE001

Identifier Type: -

Identifier Source: org_study_id